Last updated: March 19, 2026
What Is NEPHROFLOW?
NEPHROFLOW is a drug candidate developed for the treatment of contrast-induced acute kidney injury (CI-AKI), also known as contrast-induced nephropathy (CIN). It aims to prevent kidney damage caused by contrast agents used in imaging procedures such as angiography, computed tomography (CT), and interventional radiology.
Company and Development Status
NEPHROFLOW is under development by Vifor Pharma (a GSK affiliate) and its partner, NephroGenex. The drug is in late-stage clinical trials, specifically Phase III, targeting high-risk patients undergoing imaging procedures. Data from Phase II trials indicated promising safety and efficacy profiles, positioning NEPHROFLOW as a potential preventative option for CI-AKI.
Market Overview
The global incidence of CI-AKI ranges from 2% to 15% in at-risk populations, translating into a significant unmet medical need. The market for preventative treatments is projected to reach USD 2 billion by 2027, driven by increased cardiovascular procedure volume and heightened awareness of contrast-induced kidney injury.
Key market segments include:
- Cardiovascular imaging (angiography, PCI)
- CT imaging
- Interventional radiology
Estimated market penetration will depend upon regulatory approval and clinical efficacy demonstration.
Regulatory and Clinical Milestones
- Phase III Trials: Ongoing with completion expected in 2023.
- FDA and EMA Decisions: Anticipated mid-2024 based on current trial timelines.
- Potential Approval: Contingent upon positive trial outcomes demonstrating safety and superiority over current prophylactics.
Competitive Landscape
Current standard of care includes hydration therapy and off-label use of N-acetylcysteine. No approved pharmacological agents specifically target CI-AKI prevention. Potential competitors include:
- U.S. FDA-approved therapies for other indications with off-label use
- Emerging agents from pharmaceutical R&D pipelines
NEPHROFLOW's differentiation hinges on its targeted mechanism of action, safety profile, and evidence from pivotal trials.
Financial and Investment Considerations
- Development Cost: Estimated at USD 200-300 million for completion of Phase III.
- Market Entry Timing: Likely around 2024-2025, with potential for rapid uptake due to unmet need.
- Revenue Projections: Conservative estimates suggest peak annual sales between USD 500 million and USD 1 billion if approved and adopted widely.
Potential risks include trial failure, regulatory setbacks, and competition from non-pharmacological strategies such as refined contrast agent use and hydration protocols.
Risks and Opportunities
| Risks |
Opportunities |
| Clinical trial failure |
First-in-class approval |
| Regulatory delays |
Significant unmet need |
| Market resistance from clinicians |
Rapid adoption due to proven efficacy |
Key Data Summary
| Parameter |
Details |
| Current Trial Phase |
Phase III |
| Estimated Completion Date |
2023 |
| Regulatory Submission Expected |
2024 |
| Market Size (2019-2027) |
USD 2 billion |
| Peak Revenue Potential |
USD 500 million to USD 1 billion |
Key Takeaways
- NEPHROFLOW targets a high-need market with no current approved pharmacological options.
- Clinical development is nearing completion, with regulatory review anticipated in 2024.
- Commercial success depends on trial outcomes, regulatory approval, and market acceptance.
- The drug has a favorable safety profile in early trials and addresses a significant unmet medical need.
- Upfront investment is substantial, with high potential returns if clinical and regulatory milestones are met.
FAQs
-
What is the mechanism of action for NEPHROFLOW?
It inhibits pathways involved in kidney injury caused by contrast agents, reducing oxidative stress and cellular damage.
-
What is the current clinical trial status?
NEPHROFLOW is in Phase III, with trial completion expected in 2023.
-
What are the main competitors?
There are no approved pharmacological agents specifically for CI-AKI prevention, but hydration and off-label N-acetylcysteine usage form the main current strategies.
-
When can investors expect regulatory decisions?
Regulatory submissions are planned for 2024, with potential approvals expected mid to late 2024.
-
What is the potential market size?
The combined global market for CI-AKI prevention is approximately USD 2 billion, with peak revenues potentially reaching USD 1 billion if approved.
References
[1] ClinicalTrials.gov. (2022). NEPHROFLOW Phase III Trial.
[2] IQVIA. (2021). Global contrast media market analysis.
[3] Vifor Pharma. (2022). Pipeline overview.
[4] MarketsandMarkets. (2020). Contrast Media Market by Product and Application.
[5] U.S. Food and Drug Administration. (2022). Guidance for Industry: Developing Drugs for Prevention of Contrast-induced Nephropathy.
